William Ridgway, M.D.
Rheumatology, Allergy and Clinical Immunology
- Chief, Division of Rheumatology, Allergy & Clinical Immunology
Philosophy of Care
Many patients with autoimmune and rheumatological diseases suffer for years before a proper diagnosis is made. The history of the illness is critical to establishing a proper diagnosis in rheumatology. I emphasize a detailed history and physical examination, with confirmatory laboratory and radiological studies. Once the diagnosis is established, I believe in an evidence-based approach to treatment, emphasizing the scientific literature whenever possible (some rheumtological conditions are so rare that controlled studies are lacking).
The treatment options available in rheumatology have expanded greatly in recent years, and patients resistant to conventional therapy can now be treated with a wide variety of novel biological therapies, often specifically targeted to the immunological basis of their disease. This gives us many tools to achieve our goal of suppressing inflammation as much as possible, thereby reducing disease activity so that the patient can resume their usual activities and lifestyle.
Dr. Ridgway is a rheumatologist, specializing in diagnosis and treatment of autoimmune and inflammatory rheumatological diseases.
Dr. Ridgway's laboratory research focuses on the immunogenetic basis of autoimmune disease, with the goal of developing novel, disease specific immunotherapies.
Rheumatology, Allergy and Clinical Immunology
M.D., University of Rochester School of Medicine, Rochester NY 1989
Post-Bac, Bryn Mawr College, Bryn Mawr PA 1985
B.A., Haverford College, Haverford PA 1982
Internship: Internal Medicine, Stanford University Hospital, Stanford CA 1989-1990
Internal Medicine, Stanford University Hospital, Stanford CA 199o-1992
Physician Postdoctoral Fellow, Howard Hughes Medical Institute, Stanford CA 1993-1996
Rheumatology/Immunology, Stanford University Hospital, Stanford CA 1992-1994
Postdoctoral Research Fellow, Stanford University School of Medicine, Stanford CA 1993-1997
American Board of Internal Medicine,
American Board of Internal Medicine, Rheumatology,
Medical Board of California,
American Association of Immunologists (AAI)
American College of Physicians (ACP)
American College of Rheumatology
Central Society for Clinical Research
Honors and Awards
Department of IM Distinguished Research Achievement Award, 2013
Alice W. and Mark A. Brown Endowed Chair of IM, 2010
Co-award: H.M. Margolis Research Grant, 1999
Pfizer Faculty Scholar, Immunology/Rheumatology, Juvenile Diabetes Foundation International Career Development Award, 1999
Howard Hughes Medical Institute, Post doctoral Fellow, Stanford University, 1993
Alpha Omega Alpha, 1989
Magna cum Laude, Departmental High Honors, Departmental First Prize, 1982
Phi Beta Kappa, 1982
Select Recent Publications
Itoh A, Ortiz L, Kachapati K, Yuehong Wu, Adams D, Bednar K, Mukherjee S, Chougnet C, Chen YG, Mittler R, Dolan L, Ridgway WM. Soluble CD137 ameliorates acute type 1 diabetes by inducing T cell anergy. Frontiers in Immunology. 2019 Nov 7;10:2566.
Zhang W, Zhang R, Zhang J, Sun Y, Leung P, Yang GX, Shuai Z, Ridgway W, Gershwin ME. Dynamic Proteomic Analysis Reveals Distinctive Protein Profiles Involved in CD8 T Cell-Mediated Murine Autoimmune Cholangitis. Cell Mol Immunol. 2018;15:756-767.
Huang W, Rainbow DB, Wu Y, Adams D, Shivakumar P, Kottyan L, Aronow B, Karns R, Bezerra J, Gershwin ME, Wicker LS, Ridgway WM. A Novel Pkhd1 mutation interacts with the Nonobese diabetic (NOD) genetic background to cause autoimmune cholangitis. Journal of Immunology. 2017;200:147-162.
Itoh A, Irie J, Tagawa H, Kusumoto Y, Kato M, Kobayashi N, Tanaka K,Kikuchi R, Fujita M, Nakajima Y, Wu Y, Yamada S, Kawai T, Ridgway WM, Itoh H. GLP-1 receptor agonist, liraglutide, ameliorates hepatosteatosis induced by anti-CD3 antibody in female mice. J Diabetes Complications. 2017;31:1370-1375.
Ito A, Ridgway WM. Targeting innate immunity to down-modulate adaptive immunity and reverse type 1 diabetes. ImmunoTargets and Therapy Immunotargets Ther. 2017;6:31-38.
Forsberg MH, Ciecko AE, Bednar KJ, Itoh A, KritikaKachapati, Ridgway WM, Chen YG. CD137 plays both pathogenic and protective roles in type 1 diabetes development in NOD mice. J Immunol. 2017;198:3857-3868.
Ma HD, Ma WT, Liu QZ, Zhao ZB, Liu MZY, Tsuneyama K, Gao JM, Ridgway WM, Ansari AA, Gershwin ME, Fei YY, Lian ZX. Chemokine Receptor CXCR3 Deficiency Exacerbates Murine Autoimmune Cholangitis by Promoting Pathogenic CD8+ T Cell Activation. Journal of Autoimmunity. 2017;78:19-28.
Yang GX, Sun Y, Tsuneyama K, Zhang W, Leung PS, He XS, Ansari AA, Bowlus C, Ridgway WM, Gershwin ME. Endogenous interleukin-22 protects against inflammatory bowel disease but not autoimmune cholangitis in dominant negative form of transforming growth factor beta receptor type II mice. Clin Exp Immunol. 2016;185:154-164.
Yang JB, Wang YH, Yang W, Lu FT, Ma HD, Zhao ZB, Jia YJ, Tang W, Tsuneyama K, Ridgway WM, Gershwin ME, Lian ZX. Successful treatment of murine autoimmune cholangitis by parabiosis: Implications for hematopoietic therapy. Journal of Autoimmunity. 2015;66:108-117.
Bednar K, Tsukamoto H, Kachapati K, Ohta S, Wu Y, Katz J. Ascherman D; Ridgway, WM. Reversal of New Onset Type 1 Diabetes with an agonistic TLR4/MD-2 Monoclonal Antibody. Diabetes. 2015;64:3614-3626.